Peregrine Capital Management LLC lowered its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 14.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 110,313 shares of the medical instruments supplier's stock after selling 18,094 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.22% of Haemonetics worth $9,433,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also added to or reduced their stakes in the company. Meeder Asset Management Inc. boosted its position in shares of Haemonetics by 65.2% during the 4th quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 135 shares during the last quarter. State of Wyoming bought a new stake in shares of Haemonetics during the 4th quarter valued at about $28,000. Carmel Capital Partners LLC bought a new stake in shares of Haemonetics during the 3rd quarter valued at about $30,000. Belpointe Asset Management LLC boosted its position in shares of Haemonetics by 65.5% during the 1st quarter. Belpointe Asset Management LLC now owns 455 shares of the medical instruments supplier's stock valued at $38,000 after acquiring an additional 180 shares during the last quarter. Finally, AdvisorNet Financial Inc boosted its position in shares of Haemonetics by 3,963.6% during the 3rd quarter. AdvisorNet Financial Inc now owns 447 shares of the medical instruments supplier's stock valued at $40,000 after acquiring an additional 436 shares during the last quarter. Institutional investors own 99.67% of the company's stock.
Haemonetics Price Performance
Shares of NYSE HAE traded down $0.89 during trading hours on Wednesday, reaching $86.17. 398,286 shares of the stock traded hands, compared to its average volume of 449,810. The company has a market capitalization of $4.38 billion, a P/E ratio of 35.03, a price-to-earnings-growth ratio of 2.01 and a beta of 0.36. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. Haemonetics Co. has a 52-week low of $70.74 and a 52-week high of $95.26. The company's 50-day simple moving average is $77.89 and its two-hundred day simple moving average is $82.93.
Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, beating analysts' consensus estimates of $0.94 by $0.10. The company had revenue of $336.20 million for the quarter, compared to analysts' expectations of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. Haemonetics's revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period last year, the firm posted $0.85 EPS. Equities research analysts forecast that Haemonetics Co. will post 3.95 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on HAE. StockNews.com downgraded Haemonetics from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. TheStreet cut Haemonetics from a "b-" rating to a "c+" rating in a report on Thursday, February 29th. Finally, Barrington Research reissued an "outperform" rating and set a $105.00 price objective on shares of Haemonetics in a report on Tuesday, February 13th.
Check Out Our Latest Analysis on HAE
About Haemonetics
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.
Read More
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
